| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Thyroid hormone receptors (TRα and TRβ). 3,5-Diiodothyropropionic acid is a thyroid hormone analog that binds to thyroid hormone receptors. It may act as an agonist or partial agonist at these receptors, modulating gene expression and metabolic processes. The compound has been studied for its potential to mimic the effects of thyroid hormones without the full spectrum of side effects. It may also interact with other cellular targets involved in metabolism and cardiovascular function.
|
|---|---|
| ln Vitro |
3,5-Diiodothyropropionic acid is a thyroid hormone analog that has been studied for its biological activities. It binds to thyroid hormone receptors and may modulate metabolic processes. The compound has been investigated for its potential use in metabolic disorders and cardiovascular diseases. As a diiodinated derivative, it is less potent than triiodothyronine (T3) but may have a more favorable side effect profile. The compound has been studied in models of hyperlipidemia, obesity, and heart failure.
|
| ln Vivo |
In vivo, 3,5-Diiodothyropropionic acid has been studied in animal models for its metabolic and cardiovascular effects. It has been shown to reduce serum cholesterol and triglyceride levels in animal models of hyperlipidemia. The compound may also have positive inotropic effects on the heart, making it a potential treatment for heart failure. It has been studied in models of obesity for its effects on weight loss and energy expenditure.
|
| Enzyme Assay |
In vitro receptor binding assays are performed using nuclear extracts or membrane preparations from cells expressing thyroid hormone receptors (TRα and TRβ). Increasing concentrations of 3,5-Diiodothyropropionic acid (0.01 nM - 10 μM) are incubated with a fixed concentration of radiolabeled T3 (e.g., [¹²⁵I]-T3) in assay buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.1% BSA) for 60-120 minutes at room temperature. Nonspecific binding is determined using 1 μM unlabeled T3. Bound radioactivity is separated by filtration or precipitation and quantified. IC50 or Ki values are calculated. Receptor activation can be assessed using reporter gene assays.
|
| Cell Assay |
Cell-based assays for 3,5-Diiodothyropropionic acid are performed using cells expressing thyroid hormone receptors (TRα and TRβ) and a thyroid hormone response element (TRE)-driven luciferase reporter. Cells are treated with varying concentrations of the compound (0.01 nM - 10 μM) for 24-48 hours. Luciferase activity is measured after addition of substrate. EC50 values are calculated from dose-response curves. The compound's efficacy as an agonist or antagonist is determined by comparison with T3. Cellular metabolic assays (e.g., oxygen consumption rate, glucose uptake) may also be performed to assess functional effects.
|
| Animal Protocol |
In animal studies, 3,5-Diiodothyropropionic acid is typically administered orally or intraperitoneally to rodents. For hyperlipidemia studies, animals are fed a high-fat diet and treated with the compound. Serum cholesterol, triglycerides, and other lipid parameters are measured. For heart failure studies, cardiac function is assessed by echocardiography. For obesity studies, body weight, food intake, and energy expenditure are monitored. Doses are selected based on preliminary pharmacokinetic and tolerability assessments.
|
| ADME/Pharmacokinetics |
3,5-Diiodothyropropionic acid is a thyroid hormone analog with a molecular weight of approximately 528.1 and formula C15H12I2O4. As a small molecule, it is expected to have reasonable oral bioavailability. The compound contains two iodine atoms, which contribute to its lipophilicity and receptor binding affinity. It should be stored as powder under appropriate conditions. The compound is stable when stored properly. Solubility in aqueous and organic solvents should be determined experimentally.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are documented for 3,5-Diiodothyropropionic acid. As a thyroid hormone analog, it may cause side effects related to thyroid hormone excess, including tachycardia, arrhythmias, weight loss, anxiety, and bone loss at high doses. The compound should be handled with appropriate safety precautions. It is intended for research use only and is not approved for human therapeutic applications. Standard laboratory safety practices should be followed when handling the compound.
|
| References | |
| Additional Infomation |
3,5-Diiodothyronine propionate (DITPA) is a monocarboxylic acid, namely (4-hydroxy-3,5-diiodophenyl)propionate, in which the phenolic hydroxyl group is replaced by a 4-hydroxyphenyl group. It is an ionic analog of levothyroxine. It is an organoiodine compound, an aromatic ether, a phenolic compound, and a monocarboxylic acid. DITPA has been used in research on congestive heart failure.
3,5-Diiodothyropropionic acid is also known as DITPA or 3,5-diiodo-4-(4-hydroxyphenoxy)benzenepropanoic acid. It is a thyroid hormone analog that has been studied for its potential use in metabolic disorders and cardiovascular diseases. The compound binds to thyroid hormone receptors and modulates metabolic processes. It has been investigated for its effects on serum lipids, cardiac function, and body weight. The compound is intended for research use only. |
| Molecular Formula |
C15H12O4I2
|
|---|---|
| Molecular Weight |
510.06138
|
| Exact Mass |
509.883
|
| CAS # |
1158-10-7
|
| PubChem CID |
160565
|
| Appearance |
White to off-white solid powder
|
| Density |
2.068g/cm3
|
| Boiling Point |
535.3ºC at 760mmHg
|
| Flash Point |
277.6ºC
|
| Vapour Pressure |
2.72E-12mmHg at 25°C
|
| Index of Refraction |
1.708
|
| LogP |
4.41
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
21
|
| Complexity |
333
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
WONYMNWUJVKVII-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H12I2O4/c16-12-7-9(1-6-14(19)20)8-13(17)15(12)21-11-4-2-10(18)3-5-11/h2-5,7-8,18H,1,6H2,(H,19,20)
|
| Chemical Name |
3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~98.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.90 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.90 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9606 mL | 9.8028 mL | 19.6055 mL | |
| 5 mM | 0.3921 mL | 1.9606 mL | 3.9211 mL | |
| 10 mM | 0.1961 mL | 0.9803 mL | 1.9606 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
